Biotech Values

[rogerm]

I would have preferred seeing the 64mg arm coming out on top on the BACS but any improvement on a cognitive scale is a rarity and nice to see the 32mg do well. The part of the paper I liked best was MIN-101 had a clinical meaningful effect in about 40% of patients.

"Cohen described a 0.5 SD effect size as “visible to the naked eye.” Given the distributional properties of change in this study, about 40% of participants demonstrate an improvement of 0.5 or greater, suggesting that a substantial minority of participants experienced benefit that was clinically meaningful."

Note the BACS is not being used as a primary or secondary endpoint in the ongoing 500 patient P3 neg symptoms in Schizo trial. As an aside the author of the paper happens to also be the inventor of BACS.